semaglutides brands FDA Warns on Certain Forms of Compounded Semaglutide Generic Semaglutide in USA (2026):

There is no sign of systemic disease

Conus, Lausanne (Psychiatrie)

Ideal candidates might include those who: Have documented binge eating episodes causing significant distress Meet BMI criteria for weight management medications Have not responded adequately to psychological interventions (such as cognitive behavioural therapy) Do not have contraindications to GLP-1 therapy Understand the off-label nature of this indication UK SmPCs for GLP-1 medications note findings of thyroid C-cell tumours in rodent studies, though the relevance to humans remains uncertain

The study compared periods when individuals were taking these medications to periods when they were not, using a within-individual design